Neoadjuvant etoposide, ifosfamide, and cisplatin for the treatment of olfactory neuroblastoma.

Indicated for olfactory neuroblastoma (ethesioneuroblastoma). The aim of the study was to evaluate the efficacy of neoadjuvant chemotherapy with the combination of etoposide, ifosfamide and cisplatin (VIP) for patients with olfactory neuroblastoma.

Official Title

Conditions

Study Type

Retrospective analysis

Study Design

After chemotherapy radiotherapy and/or surgery according to tumor response was planned.

Further Details

Treatment involved: Etoposide 75 mg/m2 i.v. (90 min) d1-5Ifosfamide 1000 mg/m2 i.v. (1h inf.) d1-5 with mesnaCisplatin 20 mg/m2 i.v. (15 min) d1-5Repeated every 3 weeks.Efficacy: CR: 2 (18.2%)PR: 7 (63.6%)SD: 2 (18.2%)Median survival: 18 months.Tolerability:Toxicity (WHO criteria) after a total of 46 cycles.Grade 3 / 4 Neutropenia was observed after 17 cycles (37%), and febrile neutropenia was observed after 2 treatment cycles. In future studies, the administration of prophylactic G-CSF will be considered. No grade 3 / 4 non-hematologic side effects, except nausea and alopecia occurred. Toxicity was reversible, and there were no treatment-related deaths.Conclusions:Neoadjuvant VIP chemotherapy was active in the treatment of olfactory neuroblastoma (but is not curative alone). Combined-modality approaches involving surgery and/or RT are essential for achieving long-term disease control.